<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01257178</url>
  </required_header>
  <id_info>
    <org_study_id>12809</org_study_id>
    <secondary_id>I2K-MC-ZZBL</secondary_id>
    <nct_id>NCT01257178</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Pharmacokinetics of LY2624803 in Subjects With Hepatic Impairment</brief_title>
  <official_title>A Single Dose Pharmacokinetics Study of LY2624803 in Subjects With Hepatic Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the impact of hepatic dysfunction on the&#xD;
      pharmacokinetics and safety of LY2624803 and its major metabolite, LSN2797276.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Trial was Terminated prior to subjects receiving study drug; no trial results&#xD;
  </why_stopped>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>LY2624803 and the metabolite LSN2797276 Area under the Curve from time 0 to infinity [AUC(0-∞)]</measure>
    <time_frame>Predose through 120 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>LY2624803 and the metabolite LSN2797276, Maximum Concentration (Cmax)</measure>
    <time_frame>Predose through 120 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>LY2624803 and the metabolite LSN2797276, Time to maximum plasma concentration(tmax)</measure>
    <time_frame>Predose through 120 hours post dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>LY2624803 and the metabolite LSN2797276, Elimination half live (t1/2)</measure>
    <time_frame>Predose through 120 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LY2624803 and the metabolite LSN2797276, AUC to the last quantifiable sample [AUC(0-tlast)]</measure>
    <time_frame>Predose through 120 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LY2624803 and the metabolite LSN2797276, Apparent clearance (CL/F)</measure>
    <time_frame>Predose through 120 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LY2624803 and the metabolite LSN2797276, Apparent volume of distribution (V/F)</measure>
    <time_frame>Predose through 120 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LY2624803 and the metabolite LSN2797276, Parent to metabolite ratios (MR) of Cmax</measure>
    <time_frame>Predose through 120 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LY2624803 and the metabolite LSN2797276, Parent to metabolite ratios (MR) of AUC</measure>
    <time_frame>Predose through 120 hours post dose</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Insomnia</condition>
  <arm_group>
    <arm_group_label>Normal hepatic function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6mg, oral, once on day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mild hepatic impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 mg, oral, once on day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate hepatic impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 mg, oral, once on day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Severe hepatic impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 mg, oral, once on day 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2624803</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Mild hepatic impairment</arm_group_label>
    <arm_group_label>Moderate hepatic impairment</arm_group_label>
    <arm_group_label>Normal hepatic function</arm_group_label>
    <arm_group_label>Severe hepatic impairment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        All Subjects&#xD;
&#xD;
          -  Sexually active male and female subjects and their partners must agree to use 2&#xD;
             methods of contraception such as condom or occlusive cap (diaphragm or cervical/vault&#xD;
             caps) together with spermicidal foam/gel/film/cream/suppository, from the time the&#xD;
             subject enters the study until 3 months after the final dosing occasion, unless the&#xD;
             male subject or partner has been sterilized (with confirmed azoospermia).&#xD;
&#xD;
          -  Have a BMI between 18.5 and 35.0 kg/m2, inclusive.&#xD;
&#xD;
          -  Have a body weight &gt;50 kg.&#xD;
&#xD;
          -  Have normal sitting blood pressure and heart rate compatible with their disease state,&#xD;
             as determined by the investigator.&#xD;
&#xD;
          -  Have venous access sufficient to allow blood sampling as per the protocol.&#xD;
&#xD;
          -  Are reliable and willing to make themselves available for the duration of the study&#xD;
             and are willing to follow study procedures.&#xD;
&#xD;
          -  Have given written informed consent approved by Lilly and the Ethical Review Board&#xD;
             governing the site.&#xD;
&#xD;
        Control Subjects&#xD;
&#xD;
          -  Are males or females and with normal hepatic function, as determined by medical&#xD;
             history and physical examination.&#xD;
&#xD;
          -  Have clinical laboratory test results within normal reference range for the&#xD;
             investigator site, or results with minor deviations not considered to be clinically&#xD;
             significant by the investigator.&#xD;
&#xD;
        Hepatic Impaired Subjects&#xD;
&#xD;
        •Have stable hepatic impairment (alcoholic, posthepatitis, biliary cirrhosis, cryptogenic)&#xD;
        classified as Child-Pugh class A, B, or C (mild, moderate, and severe impairment) who are&#xD;
        considered acceptable for participation in the study by the investigator.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        All Subjects&#xD;
&#xD;
          -  Are currently enrolled in, or discontinued within the last 90 days from the last&#xD;
             dosing occasion in a clinical trial involving an investigational drug or device, or&#xD;
             are concurrently enrolled in any other type of medical research judged not to be&#xD;
             scientifically or medically compatible with this study.&#xD;
&#xD;
          -  Have known allergies to LY2624803 or related compounds.&#xD;
&#xD;
          -  Have previously discontinued from this study or any other study investigating&#xD;
             LY2624803.&#xD;
&#xD;
          -  Have an abnormality in the 12-lead ECG that, in the opinion of the investigator,&#xD;
             increases the risk associated with participating in the study.&#xD;
&#xD;
          -  Regularly use known drugs of abuse and/or show positive findings on urinary drug&#xD;
             screening.&#xD;
&#xD;
          -  Show evidence of human immunodeficiency virus (HIV) and/or positive HIV antibodies.&#xD;
&#xD;
          -  Have donated blood of more than 500 mL within the last 3 months prior to the screening&#xD;
             visit.&#xD;
&#xD;
          -  Use drugs or herbal remedies that are known inhibitors or inducers of CYP3A4 or&#xD;
             inhibitors of CYP2D6 enzyme pathways, unless in the opinion of the sponsor and&#xD;
             investigator the medication will not compromise safety.&#xD;
&#xD;
          -  Are liver transplant subjects or have taken immunosuppressants following any organ&#xD;
             transplant.&#xD;
&#xD;
          -  Have shown signs of variceal bleeding during the last 2 weeks prior to screening.&#xD;
&#xD;
          -  Show evidence of irritable bowel syndrome or chronic diarrhea.&#xD;
&#xD;
          -  Have an average weekly alcohol intake that exceeds 28 units per week (males) and 21&#xD;
             units per week (females), and are subjects unwilling to stop alcohol consumption for&#xD;
             the duration of the study (1 unit = 12 oz or 360 mL of beer; 5 oz or 150 mL of wine;&#xD;
             1.5 oz or 45 mL of distilled spirits).&#xD;
&#xD;
          -  Are unable to swallow whole capsules.&#xD;
&#xD;
          -  Are on total parenteral nutrition (TPN).&#xD;
&#xD;
          -  Take anticoagulants for therapeutic use.&#xD;
&#xD;
          -  Have a history of breast cancer.&#xD;
&#xD;
          -  Exhibit any other condition, which, in the opinion of the investigator would preclude&#xD;
             participation in the study.&#xD;
&#xD;
        Control Subjects&#xD;
&#xD;
          -  Have any medically significant history of neurologic disease, cancer, or cardiac,&#xD;
             respiratory, metabolic, hepatic, renal, gastrointestinal (except appendectomy),&#xD;
             dermatological, venereal, hematological disorder or disease.&#xD;
&#xD;
          -  Have creatinine clearance (CrCl) &lt;80 mL/min, as calculated by Cockcroft-Gault&#xD;
             equation.&#xD;
&#xD;
          -  Show evidence of significant active neuropsychiatric disease in the opinion of the&#xD;
             investigator.&#xD;
&#xD;
          -  Show evidence of hepatitis B and/or positive hepatitis B surface antigen (HBsAg).&#xD;
&#xD;
          -  Show evidence of hepatitis C and/or positive hepatitis C antibody.&#xD;
&#xD;
        Mild Hepatic Impaired Subjects (Child-Pugh A)&#xD;
&#xD;
          -  Show evidence of any significant active disease other than that responsible for or&#xD;
             associated with hepatic impairment.&#xD;
&#xD;
          -  Show evidence of active renal disease with creatinine clearance &lt;70 mL/min as&#xD;
             calculated by Cockcroft-Gault equation.&#xD;
&#xD;
          -  Have severe ascites.&#xD;
&#xD;
        Moderate and Severe Hepatic Impaired Subjects (Child-Pugh B and C)&#xD;
&#xD;
          -  Show evidence of any significant active disease other than that responsible for or&#xD;
             associated with moderate or severe hepatic impairment.&#xD;
&#xD;
          -  Show evidence of hepatorenal syndrome as shown by creatinine clearance &lt;50 mL/min, as&#xD;
             calculated by the Cockcroft-Gault equation.&#xD;
&#xD;
          -  Have shown signs of spontaneous bacterial peritonitis within 6 months prior to dosing.&#xD;
&#xD;
          -  Have severe hyponatremia.&#xD;
&#xD;
          -  Have hepatic encephalopathy (grade 2 to 4 encephalopathy).&#xD;
&#xD;
          -  Show signs of hepatocellular carcinoma.&#xD;
&#xD;
          -  Have a portal shunt.&#xD;
&#xD;
          -  Show, in the opinion of the investigator, evidence of significant active&#xD;
             neuropsychiatric disease other than grade 1 hepatic encephalopathy.&#xD;
&#xD;
          -  Have severe ascites.&#xD;
&#xD;
          -  Have hemoglobin concentrations &lt;9.0 g/dL.&#xD;
&#xD;
          -  Have a platelet count of &lt;50 x 109 cells/L, unless, after consultation with the&#xD;
             sponsor, they are considered as acceptable for participation in the study.&#xD;
&#xD;
          -  Have total serum bilirubin concentrations &gt;15 mg/dL (&gt;257 µmol/L).&#xD;
&#xD;
          -  Take medications known to interfere with hepatic metabolism (for example barbiturates,&#xD;
             phenothiazines) or known to alter other major organ systems.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mitte</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Muenchen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <study_first_submitted>December 7, 2010</study_first_submitted>
  <study_first_submitted_qc>December 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2010</study_first_posted>
  <last_update_submitted>June 2, 2011</last_update_submitted>
  <last_update_submitted_qc>June 2, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2011</last_update_posted>
  <responsible_party>
    <name_title>Chief Medical Officer</name_title>
    <organization>Eli Lilly</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

